EUCTR2016-002213-21-GB进行中（未招募）1 期
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL PROOF OF CONCEPT STUDY TO EVALUATE THE EFFECTS OF MULTIPLE ORAL DOSES OF TASIMELTEON AND MATCHING PLACEBO IN TRAVELERS WITH JET LAG DISORDER - VP-VEC-162-2102 Tasimelteon in travellers with jet lag disorder
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Ability and acceptance to provide written informed consent
- •2. Men or women between 18 – 75 years, inclusive
- •3. A Jet Lag Symptom Scale (JLSS) total score of = 4 AND at least one night of Sleep Efficiency = 85% during the first two thirds of any night. The JLSS will be determined as follows: Subjects will receive a score of 2 for Sleep Efficiency that is = 80% or receive a score of 1 if it is = 85% during the first two thirds of the 8-hour sleep period on each night. Subjects will also receive a score of 2 for an average KSS score of = 6 for each day. All the scores across 3 nights and 3 days will be added as the total score ranging from 0 to 12.
- •4. Body Mass Index (BMI) of = 18 and = 30 kg/m2 (BMI = weight (kg)/ [height (m)]2)
- •5. Valid passport for international travel and fluent in English;
- •6. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control (i.e., condoms, diaphragm, spermicidal agents, cervical cap) for a period of 35 days before the first dosing, during the study and for one month after the last dose and must have a negative pregnancy test at the screening and baseline and D1 visits;
- •a. Note: Women using hormonal methods of birth control must use an additional method of birth control during the study and for one month after the last dose. Valid passport for international travel and fluent in English
- •7. In good health as determined by a medical and psychiatric history, physical examination, Electrocardiogram, and serum chemistry and hematology
- •8. Willing to comply with study procedures and restrictions with fixed sleep time and wake time during the study and to attend regularly scheduled clinic visits as specified in this protocol
- •9. Has negative urine test result for selected substances of abuse at V1- through the end of the randomization phase
- •10. Has not used pharmacological sleep assistance more than 4 times/month during the 3 months prior to screening
- •11. Must have discontinued use of all pharmacological sleep aids beginning 1 week prior to Visit 2 and for the duration of the trial
- •12. Must have a target daily bedtime that on average occurs between 21:00 and 00:00
- •13. eDiary and actigraphy must demonstrate, on average, that the total sleep time each night is between 7 to 9 hours during screening during the week preceding V2;
- •14. eDiary and actigraphy must demonstrate that on most nights (5 of the 7 days) the subject’s habitual bedtime does not differ by more than 2 hours during screening the week preceding V2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 39
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 9
排除标准
- •1. History of primary insomnia or any circadian rhythm sleep disorder, other than jet lag, as defined by ICSD-3
- •2. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures
- •3. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable
- •4. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists
- •5. Indication of impaired liver function (values for enzymes aspartate transaminase (AST) and alanine transaminase (ALT) or bilirubin > than 2 times the Upper Limit of Normal)
- •6. Clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings at screening or baseline as determined by the clinical investigator
- •7. Major surgery, trauma (including broken pelvis/legs), illness (e.g. sepsis, stroke) or immobile for 3 or more days within the past month
- •8. Current smoker or quit smoking within the last 30 days
- •9. Active cancer or cancer treatment within the past 6 months
- •10. Central venous catheter in place or within the past month
- •11. History of pulmonary embolism /deep vein thrombosis (DVT) or short term blood thinner treatment as an outpatient (e.g. Coumadin, Lovenox, heparin)
- •12. History or family history of thrombosis or hypercoagulable state (e.g. Factor V Leiden, Factor VIII deficiency, Protein C & S deficiency)
- •13. Pregnancy or recent pregnancy (within 6 weeks)
- •14. History of restless leg syndrome, sleep apnea, or periodic limb movement disorder and or have current diagnosis as confirmed by the diagnostic PSG in VP-VEC-162-0101
- •15. Habitual bedtime varies by more than two hours, on average
- •16. History or evidence of excessive daytime sleepiness as determined by a score of more than 10 on the Epworth Sleepiness Scale;
- •17. History of drug or alcohol abuse as defined in DSM-V, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (> 2 drinks/day or > 14 drinks/week)
- •18. A positive test for drugs of abuse at the screening visit;
- •19. Traveled more than three time zones 2 weeks prior to the screening visit until the travel period.
- •20. Traveled outside the origination time zone within 1 week before the end of the screening period.
- •21. An average bedtime that varies more than 2 hours per week than the target bedtime during the weeks between the screening visit and the baseline visit based on patient reported sleep diaries and actigraphy.
- •22. Worked night, rotating, or split (period of work, followed by break, and then return to work) shift work within 1 month of the screening visit.
- •23. Participation in a previous tasimelteon (aka VEC-162 or BMS-214778) trial (does not pertain to VP-VEC-162-0101)
研究者
相似试验
进行中（未招募）
1 期
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL CCR5 ANTAGONIST, UK-427,857, IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY VERSUS OPTIMIZED BACKGROUND THERAPY ALONE FOR THE TREATMENT OF ANTIRETROVIRAL EXPERIENCED, NON CCR5-TROPIC HIV-1 INFECTED SUBJECTSK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in individuals HIV-1 positive.EUCTR2004-001779-20-GBPfizer Limited186
进行中（未招募）
1 期
A Study of RO6885247 in Adult and Pediatric Patients with Spinal Muscular Atrophy (MOONFISH)MedDRA version: 18.0Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2014-002246-41-ESRoche Farma S.A., en nombre de F. Hoffmann-La Roche Ltd.64
进行中（未招募）
1 期
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF DAXDILIMAB IN ADULT PARTICIPANTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITISACTIVE PROLIFERATIVE LUPUS NEPHRITISMedDRA version: 21.1Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2022-001377-31-ESHorizon Therapeutics Ireland DAC210
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 FIXED DOSES (50 mg, 100 mg) OF DESVENLAFAXINE SUSTAINED-RELEASE TABLETS IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDERMajor Depressive Disorder in outpatientsEUCTR2005-005463-28-LTWyeth Pharmaceuticals France, Wyeth Research Division480
尚未招募
不适用
ot availablePER-003-10TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,